Form 4: Moderna Chief Legal Officer Reports Routine Stock Transactions Following RSU Vesting

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the acquisition of common stock through the vesting of restricted stock units and the subsequent disposition of shares to cover tax obligations.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc. (MRNA), reported transactions involving the company's common stock.
• On May 27, 2025, Klinger acquired 773 shares of common stock through the conversion of restricted stock units (RSUs) and disposed of 374 shares at a price of $26.26 to satisfy tax withholding obligations.
• Following these transactions on May 27, 2025, Klinger beneficially owned 26,011 shares of common stock directly.
• On May 28, 2025, Klinger acquired an additional 328 shares of common stock from RSU conversion and disposed of 159 shares at a price of $26.76 for tax withholding.
• After the May 28, 2025 transactions, Klinger's direct beneficial ownership of common stock increased to 26,180 shares.
• The RSU awards convert into common stock on a one-for-one basis.
• One RSU award (related to the 773 shares) had 25% of its shares vest on February 27, 2025, with the remainder vesting in twelve equal quarterly installments.
• Another RSU award (related to the 328 shares) had 25% of its shares vest on February 28, 2024, with the remainder vesting in twelve equal quarterly installments.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions represent routine compensation events (RSU vesting) rather than discretionary sales, indicating continued alignment of the executive's interests with the company. The disposition of shares is solely for tax purposes.

Positives

• The acquisition of common stock by the Chief Legal Officer through RSU vesting indicates continued alignment of management's interests with shareholders.
• The vesting of restricted stock units is a routine compensation event, reflecting the achievement of employment milestones.

Negatives

• A portion of the acquired shares was immediately disposed of to cover tax withholding obligations, which is a common practice but not a discretionary purchase.

Future Outlook

This Form 4 filing does not provide a future outlook for the company. It details past and current insider transactions related to compensation.

Industry Context

This Form 4 filing reports routine insider transactions for Moderna's Chief Legal Officer, which is a standard disclosure for publicly traded companies. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transactions represent routine compensation for an executive, which is a standard part of corporate governance and executive incentive structures. The slight increase in direct beneficial ownership after the transactions indicates continued executive stake in the company.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The remaining portions of the restricted stock unit awards are scheduled to vest in twelve equal quarterly installments following their initial vesting dates (February 28, 2024, and February 27, 2025).

Key Dates

Keywords

Moderna, MRNA, Shannon Thyme Klinger, Chief Legal Officer, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transactions, Tax Withholding, Beneficial Ownership